Logo image of APLS

APELLIS PHARMACEUTICALS INC (APLS) Stock Price, Quote, News and Overview

NASDAQ:APLS - Nasdaq - US03753U1060 - Common Stock - Currency: USD

17.69  -0.07 (-0.39%)

After market: 17.69 0 (0%)

APLS Quote, Performance and Key Statistics

APELLIS PHARMACEUTICALS INC

NASDAQ:APLS (6/20/2025, 8:15:27 PM)

After market: 17.69 0 (0%)

17.69

-0.07 (-0.39%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High42.47
52 Week Low16.1
Market Cap2.22B
Shares125.68M
Float106.62M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)07-30 2025-07-30/bmo
IPO11-09 2017-11-09


APLS short term performance overview.The bars show the price performance of APLS in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -10 -20 -30 -40

APLS long term performance overview.The bars show the price performance of APLS in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of APLS is 17.69 USD. In the past month the price increased by 1.55%. In the past year, price decreased by -53.53%.

APELLIS PHARMACEUTICALS INC / APLS Daily stock chart

APLS Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.04 327.31B
AMGN AMGEN INC 13.94 155.58B
GILD GILEAD SCIENCES INC 14.02 134.97B
VRTX VERTEX PHARMACEUTICALS INC N/A 113.22B
REGN REGENERON PHARMACEUTICALS 11.5 55.03B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 40.38B
ARGX ARGENX SE - ADR 94.29 33.10B
ONC BEONE MEDICINES LTD-ADR 6.32 26.73B
BNTX BIONTECH SE-ADR N/A 25.61B
NTRA NATERA INC N/A 23.47B
INSM INSMED INC N/A 18.70B
BIIB BIOGEN INC 8.03 18.62B

About APLS

Company Profile

APLS logo image Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. The company is headquartered in Waltham, Massachusetts and currently employs 705 full-time employees. The company went IPO on 2017-11-09. The firm is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan), is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and United Kingdom.

Company Info

APELLIS PHARMACEUTICALS INC

100 Fifth Avenue

Waltham MASSACHUSETTS 02451 US

CEO: Cedric Francois

Employees: 708

APLS Company Website

APLS Investor Relations

Phone: 16179775700

APELLIS PHARMACEUTICALS INC / APLS FAQ

What is the stock price of APELLIS PHARMACEUTICALS INC today?

The current stock price of APLS is 17.69 USD. The price decreased by -0.39% in the last trading session.


What is the ticker symbol for APELLIS PHARMACEUTICALS INC stock?

The exchange symbol of APELLIS PHARMACEUTICALS INC is APLS and it is listed on the Nasdaq exchange.


On which exchange is APLS stock listed?

APLS stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for APELLIS PHARMACEUTICALS INC stock?

29 analysts have analysed APLS and the average price target is 36.08 USD. This implies a price increase of 103.93% is expected in the next year compared to the current price of 17.69. Check the APELLIS PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is APELLIS PHARMACEUTICALS INC worth?

APELLIS PHARMACEUTICALS INC (APLS) has a market capitalization of 2.22B USD. This makes APLS a Mid Cap stock.


How many employees does APELLIS PHARMACEUTICALS INC have?

APELLIS PHARMACEUTICALS INC (APLS) currently has 708 employees.


What are the support and resistance levels for APELLIS PHARMACEUTICALS INC (APLS) stock?

APELLIS PHARMACEUTICALS INC (APLS) has a resistance level at 18.27. Check the full technical report for a detailed analysis of APLS support and resistance levels.


Is APELLIS PHARMACEUTICALS INC (APLS) expected to grow?

The Revenue of APELLIS PHARMACEUTICALS INC (APLS) is expected to grow by 0.89% in the next year. Check the estimates tab for more information on the APLS EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy APELLIS PHARMACEUTICALS INC (APLS) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does APELLIS PHARMACEUTICALS INC (APLS) stock pay dividends?

APLS does not pay a dividend.


When does APELLIS PHARMACEUTICALS INC (APLS) report earnings?

APELLIS PHARMACEUTICALS INC (APLS) will report earnings on 2025-07-30, before the market open.


What is the Price/Earnings (PE) ratio of APELLIS PHARMACEUTICALS INC (APLS)?

APELLIS PHARMACEUTICALS INC (APLS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.77).


What is the Short Interest ratio of APELLIS PHARMACEUTICALS INC (APLS) stock?

The outstanding short interest for APELLIS PHARMACEUTICALS INC (APLS) is 23.48% of its float. Check the ownership tab for more information on the APLS short interest.


APLS Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to APLS. When comparing the yearly performance of all stocks, APLS is a bad performer in the overall market: 93.68% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

APLS Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to APLS. APLS has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

APLS Financial Highlights

Over the last trailing twelve months APLS reported a non-GAAP Earnings per Share(EPS) of -1.77. The EPS increased by 47.01% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -27.71%
ROE -136.21%
Debt/Equity 2.76
Chartmill High Growth Momentum
EPS Q2Q%-76.19%
Sales Q2Q%-3.21%
EPS 1Y (TTM)47.01%
Revenue 1Y (TTM)48.03%

APLS Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 79% to APLS. The Buy consensus is the average rating of analysts ratings from 29 analysts.

For the next year, analysts expect an EPS growth of -37.39% and a revenue growth 0.89% for APLS


Ownership
Inst Owners102.48%
Ins Owners3.77%
Short Float %23.48%
Short Ratio9.33
Analysts
Analysts78.62
Price Target36.08 (103.96%)
EPS Next Y-37.39%
Revenue Next Year0.89%